Amin Sabry M, Amr Yasser M, Fathy Sameh M, Alzeftawy Ashraf E
Department of Anesthesia, Tanta University Hospital, Tanta University, Tanta, Egypt.
Saudi J Anaesth. 2011 Oct;5(4):371-5. doi: 10.4103/1658-354X.87265.
Although nalbuphine was studied extensively in labour analgesia and was proved to be acceptable analgesics during delivery, its use as premedication before induction of general anesthesia for cesarean section is not studied. The aim of this study was to evaluate the effect of nalbuphine given before induction of general anesthesia for cesarean section on quality of general anesthesia, maternal stress response, and neonatal outcome.
Sixty full term pregnant women scheduled for elective cesarean section, randomly classified into two equal groups, group N received nalbuphine 0.2 mg/kg diluted in 10 ml of normal saline (n=30), and group C placebo (n=30) received 10 ml of normal saline 1 min before the induction of general anesthesia. Maternal heart rate and blood pressure were measured before, after induction, during surgery, and after recovery. Neonates were assisted by using APGAR0 scores, time to sustained respiration, and umbilical cord blood gas analysis.
Maternal heart rate showed significant increase in control group than nalbuphine group after intubation (88.2±4.47 versus 80.1±4.23, P<0.0001) and during surgery till delivery of baby (90.8±2.39 versus 82.6±2.60, P<0.0001) and no significant changes between both groups after delivery. MABP increased in control group than nalbuphine group after intubation (100.55±6.29 versus 88.75±6.09, P<0.0001) and during surgery till delivery of baby (98.50±2.01 versus 90.50±2.01, P<0.0001) and no significant changes between both groups after delivery. APGAR score was significantly low at one minute in nalbuphine group than control group (6.75±2.3, 8.5±0.74, respectively, P=0.0002) (27% of nalbuphine group APGAR score ranged between 4-6, while 7% in control group APGAR score ranged between 4-6 at one minute). All neonates at five minutes showed APGAR score ranged between 9-10. Time to sustained respiration was significantly longer in nalbuphine group than control group (81.8±51.4 versus 34.9±26.2 seconds, P<0.0001). The umbilical cord blood gas was comparable in both groups. None of the neonates need opioid antagonist (naloxone) or endotracheal intubation.
Administration of nalbuphine before cesarean section under general anesthesia reduces maternal stress response related to intubation and surgery, but decreases the APGAR score at one minute after delivery. So, when nalbuphine was used, all measures for neonatal monitoring and resuscitation must be available including attendance of a pediatrician.
尽管纳布啡在分娩镇痛方面得到了广泛研究,并被证明是分娩期间可接受的镇痛药,但它作为剖宫产全身麻醉诱导前的术前用药尚未得到研究。本研究的目的是评估剖宫产全身麻醉诱导前给予纳布啡对全身麻醉质量、产妇应激反应和新生儿结局的影响。
60例计划择期剖宫产的足月孕妇,随机分为两组,每组30例。N组静脉注射稀释于10ml生理盐水中的纳布啡0.2mg/kg,C组(安慰剂组)在全身麻醉诱导前1分钟静脉注射10ml生理盐水。在诱导前、诱导后、手术期间和恢复后测量产妇的心率和血压。使用阿氏评分、自主呼吸建立时间和脐血气分析评估新生儿情况。
插管后(88.2±4.47对80.1±4.23,P<0.0001)及手术至胎儿娩出期间(90.8±2.39对82.6±2.60,P<0.0001),C组产妇心率显著高于N组,分娩后两组间无显著变化。插管后(100.55±6.29对88.75±6.09,P<0.0001)及手术至胎儿娩出期间(98.50±2.01对90.50±2.01,P<0.0001),C组平均动脉压高于N组,分娩后两组间无显著变化。N组出生1分钟时阿氏评分显著低于C组(分别为6.75±2.3、8.5±0.74,P=0.0002)(N组27%的新生儿1分钟阿氏评分在4-6分之间,而C组为7%)。所有新生儿5分钟时阿氏评分在9-10分之间。N组自主呼吸建立时间显著长于C组(81.8±51.4对34.9±26.2秒,P<0.0001)。两组脐血气指标相当。无一例新生儿需要使用阿片类拮抗剂(纳洛酮)或气管插管。
剖宫产全身麻醉前给予纳布啡可降低与插管和手术相关的产妇应激反应,但会降低分娩后1分钟时的阿氏评分。因此,使用纳布啡时,必须具备所有新生儿监测和复苏措施,包括儿科医生在场。